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Diabetic autonomic neuropathy: evidence for apoptosis
in situ in the rat
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Abstract We examined the hypothesis that activation
of the apoptosis cascade occurs relatively early in
diabetes mellitus affecting three distinct neuronal
populations that are involved in regulating gut func-
tion: (i) dorsal root ganglion (DRG), (ii) vagus nodose
ganglion and (iii) colon myenteric plexus.A validated
streptozotocin-induced diabetic rat model and age-
matched healthy controls were studied. After
4–8 weeks of diabetes the animals were anaesthetized,
fixed in situ and the relevant tissues removed. After
1 month of diabetes some animals were treated with
insulin for 2 weeks to restore euglycaemia. Apoptosis
was measured using immunohistochemical detection
of activated caspase-3 and terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labelling (TU-
NEL)-positive cells in adjacent sections in neurones
(PGP 9.5-positive cells). The level of apoptosis was
confirmed using double-label assessment of caspase-3
and TUNEL in DRG preparations.Caspase-3 immu-
noreactive neurones demonstrated a range in staining
intensity. When all grades of staining were included,
6–8% of the DRG, nodose ganglia and myenteric
neurones were immunoreactive in the preparations
from diabetic rats compared with 0.2–0.5% in con-
trols. Neurones staining positive for both caspase-3
and TUNEL accounted for 1–2% of the total neuronal
population in all three preparations in diabetic rats
compared with 0.1–0.2% in controls (P < 0.05). Insulin
treatment reversed the percentage of TUNEL-positive
neurones in diabetic rats to control levels.Activation
of the apoptosis cascade occurs relatively early in
diabetic autonomic neuropathy and may contribute to
the pathophysiology of this disorder.
Keywords Diabetic neuropathy, apoptosis, autonomic
neuropathy, caspases.
INTRODUCTION
Diabetic neuropathy is the most common peripheral
neuropathy in the western hemisphere. Up to 60% of
individuals with diabetes mellitus will be afflicted
with neuropathy after 20 years from their diagnosis.1
The pathophysiology of this disorder remains unre-
solved but is likely multifactorial. Chronic hypergly-
caemia associated with diminished insulin production
or function appears to be the primary initiating factor
in the pathogenesis of diabetic complications. Several
hypotheses have been proposed to explain how diabetic
complications occur in this milieu including increased
activity of aldose reductase, impaired neurotrophin
production and function, mitochondrial dysfunction
associated with the formation of reactive oxygen
species, altered expression/function of protein kinase
C (PKC) isoforms, abnormal calcium signalling and
formation of advanced glycation end products.2–8
Diabetic autonomic neuropathy (DAN) is a well-
described complication in long-term diabetes.1 The
DAN is associated with a markedly reduced quality
of life and poor prognosis. The manifestations of
DAN cause multiple symptoms that can involve the
(i) gastrointestinal tract: oesophageal motor dysfunc-
tion, diabetic gastroparesis, gall bladder atony, dia-
betic enteropathy, colonic hypomotility, anorectal
dysfunction; (ii) respiratory system: reduced ventila-
tory drive to hypercapnia/hypoxemia, sleep apnoea;
(iii) genitourinary tract: diabetic cystopathy, erectile
dysfunction and (iv) cardiovascular system: resting
tachycardia, reduced heart rate variability and circa-
dian rhythm of heart rate and blood pressure, painless
myocardial ischaemia/infarction, orthostatic hypoten-
sion, exercise intolerance, perioperative instability,
and sudden death. Previous studies suggest that the
function of extrinsic vagal afferent and intrinsic
myenteric plexus neural pathways can be impaired
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in animal models of diabetes and patients with long-
standing diabetes.9–11
Various pathological lesions are observed in animal
and human models of diabetes including segmental
demyelination, atrophy, loss of myelinated and un-
myelinated fibres, Wallerian degeneration, segmental
and paranodal demyelination and blunted nerve fibre
generation.12,13 Axonal regeneration in the peripheral
nervous system is initially robust, but it eventually
fails for unclear reasons. Several animal models have
been employed to study the pathophysiology of type 1
and type 11 diabetes mellitus. The most well-estab-
lished model is the streptozotocin (STZ)-induced
diabetic rat model.2 This model demonstrates many of
the complications known to occur in human diabetes.
Recent reports hypothesize that activation of the
apoptosis cascade may contribute to the pathophysiol-
ogy of diabetic peripheral sensory neuropathy. This is
an attractive hypothesis because evidence suggests that
diabetic sensory neuropathy is associated with mit-
ochondrial dysfunction and formation of reactive oxy-
gen species that are observed with activation of the
apoptosis cascade.4,5,14 In addition, apoptosis has been
observed in the hippocampus in the diabetic BB/W rat,
a model of type 1 diabetes mellitus.15 Activation of the
apoptosis cascade may also contribute to the patho-
physiology of diabetic retinopthy.16 The apoptosis
hypothesis is controversial, however, because the high
level of apoptosis reported in some articles employing
in vitro methods is inconsistent with the slow,
progressive natural history of the disease.4 In addition,
counts of the total number of neurones in dorsal root
ganglia (DRG) obtained from diabetic and control rats
do not support a significant reduction in the total
number of soma after long-term diabetes in the STZ-rat
model.17,18 However, if the level of apoptosis in situ
were relatively low, for example, 1–2% in diabetic
peripheral neuropathy, it would be difficult to detect a
statistically significant difference in the total number
of neurones because the standard error in total cell
counts can range from 5 to 10%.17,18 Most studies
evaluating the presence of apoptosis in diabetic neur-
opathy have examined DRG neurones. We reported
previously that 2 weeks of insulin-mediated euglycae-
mia reversed slowing in nerve conduction velocity,
mitochondrial dysfunction and apoptosis observed in
DRGs in the STZ-diabetic rat after 1 month of diabe-
tes.5 The presence of apopotosis has not been evaluated
in either vagal afferent (nodose ganglion) or myenteric
plexus innervation of the gastrointestinal tract in
diabetes mellitus. Both neural pathways play an
essential role in regulating gut physiology and have
been implicated in the pathophysiology of DAN.19–26
Our preliminary studies indicated an in situ level of
apoptosis of 1–2% in DRG in early (4–8 weeks)
diabetic neuropathy using the Terminal deoxynucle-
otidyl transferase-mediated dUTP nick-end labelling
(TUNEL) method to measure apoptosis in the STZ-
induced diabetic rat model. The level of apoptosis in
controls was significantly less (c. 0.1%). The goal of
the current study was to confirm and extend our
preliminary studies by measuring the in situ level of
apoptosis in the peripheral nervous system in three
distinct neural populations including DRG, nodose
ganglion and colon myenteric plexus neurones. Apop-
tosis was measured in adjacent sections using two
techniques, the TUNEL method that detects charac-
teristic nicking of DNA observed in apoptosis and
immunoreactive caspase-3 using an antibody that
recognizes the activated fragment of the executioner
enzyme, caspase-3. Neurones were identified using
the neuronal-specific marker PGP 9.5. Some studies
were preformed in DRG from control and diabetic rats
using double-label immunohistochemistry detection
of TUNEL and activated caspase-3 in the same section
to confirm the results observed using adjacent slices.
Finally, some rats were treated with insulin for
2 weeks after 1 month of diabetes to determine whe-
ther apoptosis was reversible in the myenteric plexus




Rabbit polyclonal antibody to cleaved caspase-3 (1 : 50
dilution) was obtained from R&D Biosystems, Min-
neapolis, MN, USA. The antibody to detect immunor-
eactive PGP 9.5 was obtained from UltraCone, Isle of
Wight, England, UK. The TUNEL-positive cells was
assessed according to the manufacturer’s instructions
using a kit available from Boehringer Mannheim,
Mannheim, Germany. Double-label immunohisto-
chemical detection of activated caspase-3 and TUNEL
was performed according to the vendors recommended
protocol (R&D Systems).
Animal model
All the experiments described in this manuscript were
reviewed and approved by the University of Michigan
Animal Use Committee. We used male Sprague–Daw-
ley rats, age 4–6 months old for these studies as
described previously.5 Briefly, diabetes mellitus was
produced by intraperitoneal injection of STZ
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(45 mg kg)1 in citrate buffer, pH 4.5). Age-matched
control rats received an intraperitoneal injection of
citrate buffer alone. Both groups had free access to rat
chow and water. The diabetic rats did not receive
insulin and were accepted as diabetic if their fasting
glucose levels were >300 mg dL)1. Typically, glucose
levels ranged between 350 and 550 mg dL)1. Glucose
levels and weights were assessed 3 days after receiving
STZ and at the time of euthanasia. Tissue specimens
were harvested after 4–8 weeks of diabetes. Our previ-
ous studies with this model indicated that rats with
diabetes for 4–8 weeks demonstrate a variety of func-
tional abnormalities including delayed nerve conduc-
tion velocity, increased calcium influx, impaired
inhibitory G-protein function, impaired mitochondrial
function and activation of the apoptosis cascade in
acutely dissociated DRG neurones.5,27 Animals were
narcotized with carbon dioxide inhalation and imme-
diately perfused with 4% buffered paraformaldehyde
for c. 20 min via placement of a cardiac catheter. Lower
thoracic and lumbar DRGs, nodose ganglia and sec-
tions of mid-colon were removed and processed for
immunohistochemistry. Some animals were treated
with insulin after 1 month of diabetes, using LinBit, a
sustained-release insulin implant (2 U day)1 implant,
Lin Shin, Canada). After the animals were anaesthet-
ized with ketamine and xylazine, the site for implan-
tation was shaved and treated with Betadine solution.
Typically, two implants were placed s.c. with a trocar
and stylet available from the vendor. Euglycaemia was
confirmed by glucose monitoring within 1–2 h after
implantation, at c. 24 h, and when the animals were
killed. Insulin-treated animals were used for experi-
ments after 2 weeks of insulin treatment. Some dia-
betic animals were treated with sham implants.
Immunohistochemistry
Thoracic and lumbar (T-10, -11 and -12; and L-1 and -2)
DRGs and bilateral nodose ganglia were obtained from
control and diabetic rats and processed to determine
what percentage of PGP 9.5 immunoreactive cells
(neurones) were also caspase-3 immunoreactive using
an antibody that recognizes the cleaved (activated)
17–19 kDa fragment. The caspase-3 antibody recogni-
zes mouse, rat and human-activated caspase-3. Tissues
were embedded in paraffin wax and cut into 4 lm-
thick sections. PGP 9.5-positive cells and caspase-
3-positive cells were assessed using adjacent sections.
A similar approach was used to assess the percentage of
PGP 9.5-positive cells that were also TUNEL-positive.
Full-thickness sections from the mid-colon were cut in
the transverse plane (i.e. perpendicular to the longi-
tudinal muscle layer) and were processed in a similar
manner. Sections of mouse breast cancer were proc-
essed in parallel and served as a positive control for the
caspase-3 and TUNEL assays. Sections not exposed to
the primary antibody were processed as negative
controls for the assays. Specifically, the fixed tissue
specimens were dehydrated with ethanol and xylene
and embedded in paraffin by routine methods. Sections
from these blocks were then subjected to immuno-
histochemistry using the anticaspase-3 antibody and
labelling with antirabbit IgG conjugated to horseradish
peroxidase, followed by development using diam-
inobenzidine. The primary antibody for PGP 9.5
(1 : 1000 dilution) was conjugated to horseradish per-
oxidase, followed by development with diaminobenzi-
dine. Assessment of TUNEL-positive and caspase-
3-positive cells in preparations from control and
diabetic rats was performed in a blinded manner.
About 1000 PGP 9.5-positive cells were assessed in
each experiment for co-localization with either
TUNEL or activated caspase-3 immunoreactivity (IR)
in adjacent sections. To avoid duplicate counting of the
same cells counting was performed on adjacent
sections obtained at 50 lm intervals.
Some studies were performed using DRGs from
control and diabetic rats with double-label immuno-
histochemistry for TUNEL and activated caspase-3 on
the same section. The goal of these experiments was to
compare the results of the experiments using adjacent
sections with an assessment of TUNEL and activated
caspase-3 in the same section. These experiments were
conducted using a kit from R&D System, Inc.,
following the manufacturer’s protocol. Sections from
control and diabetic rats were assessed in a blinded
manner. Again, sections were obtained at 50 lm
intervals to avoid duplicate counting of the same cells.
Assessment of TUNEL and activated caspase-3 immu-
noreactive cells was confined to soma that demonstra-
ted the typical appearance of DRG neurones.
Evaluation
For activated caspase-3 IR, we used a semiquantitative
grading system because cells varied in the intensity of
staining. To a first approximation, the grades were as
follows: grade 1 – minimal-intensity staining; grade
2 – modest-intensity staining; grade 3 – moderate-
intensity staining and grade 4 – high-intensity staining.
In the evaluation of TUNEL-positive cells, neurones
were considered positive when the nuclei stained
positively and showed chromatin clumping. The num-
ber of neurones that fulfilled the criteria was expressed
as a percentage.
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Analysis
Results were compared as mean ± SE using unpaired,
two-tailed Student’s t-test. Statistical significance was
accepted at the P < 0.05 level. Statistical analysis was
based on the number of animals (n) included in each
group.
RESULTS
Animals were studied at 4–6 months of age, 4–8 weeks
following induction of diabetes with STZ. The demo-
graphic data for the rats employed in the current
studies are presented in Table 1. The changes in
bodyweight (bw) and blood glucose levels after
4–8 weeks of diabetes were similar to prior studies.5
Two weeks of insulin treatment after 1 month of
diabetes normalized the blood glucose levels and
partially reversed the bw differences between control
and diabetic rats.
DRG neurones from diabetic rats demonstrated a
significant increase in activated caspase-
3-positive and TUNEL-positive neurones
compared with controls
We routinely performed negative (processed without
exposure to the primary antibody) and positive controls
for activated caspase-3 immunoreactive cells and
TUNEL-positive cells using mouse breast cancer tis-
sue. The positive controls demonstrated reproducible
staining in a subpopulation of cells for activated
caspase-3 IR and TUNEL that were not observed in
the negative controls. Background staining was typic-
ally very low or undetectable (data not shown). Fig. 1
depicts the results in DRG from control and diabetic
rats. Neuronal soma demonstrated a range of staining
intensity for activated caspase-3 that we graded 1 [least
intense staining (+)] to 4 [most intense staining (++++)]
that are depicted in Fig. 1A, lower left panel (DRG
from diabetic rat). Fig. 1A depicts the results in
adjacent sections involving PGP 9.5-positive cells
(right panels) that were also activated caspase-3-posit-
ive (left panels) in DRG from control (top panels) and
diabetic (bottom panels) rats. The results are summar-
ized in a histogram presented in Fig. 1B for neurones
demonstrating levels 1–4 staining and only level 4
staining for caspase-3-positive neurones. When neu-
rones demonstrating grades 1–4 staining were included
in the assessment, caspase-3-positive neurones repre-
sented 0.5 ± 0.15% of the total neuronal population in
controls and 7 ± 1.8% of the neurones in DRG from
diabetic rats (n ¼ 10, P < 0.05). When assessment of
caspase-3-positive neurones was limited to cells that
demonstrated only grade 4 staining, 0.15 ± 0.08% of
control neurones and 1.6 ± 0.12% of diabetic neurones
were caspase-3-positive (n ¼ 10, P < 0.05). Representa-
tive adjacent sections in DRG from control (top panels)
and diabetic (bottom panels) rats processed for TUNEL-
positive neurones (left panels) and PGP 9.5 (right
panels) are depicted in Fig. 1C. Fig. 1D summarizes
the TUNEL data in DRG from control and diabetic
rats. The TUNEL-positive neurones were detected in
0.10 ± 0.08% of control DRG neurones and
1.8 ± 0.15% of DRG neurones from diabetic rats
(n ¼ 10, P < 0.05).
Activated caspase-3 and TUNEL-positive
neurones were significantly increased in nodose
ganglia from diabetic rats compared with controls
Fig. 2A depicts the results in adjacent sections invol-
ving PGP 9.5-positive cells (right panels) that were also
activated caspase-3-positive (left panels) in nodose
ganglia from control (top panels) and diabetic (bottom
panels) rats. The nodose ganglia obtained from diabetic
rats demonstrated variable intensity in capase-3 IR
similar to DRG neurones. When neurones demonstra-













Control 10 354.0 ± 16.9 4.1 ± 0.1 0 88.1 ± 1.9 96.0 ± 1.9
Diabetic 10 338.0 ± 17.5* 4.2 ± 0.1 1.5 ± 0.1 407 ± 22** 464 ± 12**
Diabetic + insulin 4 346.0 ± 15.8 4.2 ± 0.1 1.2 ± 0.1 392 ± 21** 92.0 ± 2.8
Bodyweight, age, duration of diabetic mellitus (DM), and blood glucose 3 days after injection of streptozotocin (STZ) and on the
experimental day in non-diabetic control and diabetic STZ rats treated or untreated by insulin. Values are mean ± SD *P < 0.05;
**P < 0.01.
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ting grades 1–4 staining were included in the assess-
ment, caspase-3-positive neurones represented
0.4 ± 0.12% of the total neuronal population in con-
trols and 6.2 ± 1.5% of the neurones in DRG from
diabetic rats (n ¼ 10, P < 0.05). When assessment of
activated caspase-3 immunoreactive neurones was
limited to cells that demonstrated grade 4 staining,





Figure 1 Dorsal root ganglion (DRG) neurones from diabetic rats demonstrated a significant increase in activated caspase-3-positive
and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling (TUNEL)-positive neurones compared with controls.
Neuronal soma demonstrated a range of staining intensity for activated caspase-3 immunoreactivity that we graded 1 [least intense
staining (+)] to 4 [most intense staining (++++)] that are depicted in (A), lower left panel (DRG from diabetic rat). (A) Depicts the
results in adjacent sections involving PGP 9.5-positive cells (right panels) that were also caspase-3-positive (left panels) in DRG
from control (top panels) and diabetic (bottom panels) rats. The results are summarized in a histogram presented in (B) for neurones
demonstrating grades 1–4 staining and only grade 4 staining for caspase-3-positive neurones. When neurones demonstrating grades
1–4 staining were included in the assessment, caspase-3-positive neurones represented 0.5 ± 0.15% of the total neuronal population
in controls and 7 ± 1.8% of the neurones in DRG from diabetic rats (n ¼ 10, P < 0.05). When assessment of caspase-3-positive
neurones was limited to cells that demonstrated only grade 4 staining, 0.15 ± 0.08% of control neurones and 1.6 ± 0.12% of
diabetic neurones were caspase-3-positive (n ¼ 10, P < 0.05). Representative adjacent sections in DRG from control (top panels) and
diabetic (bottom panels) rats processed for TUNEL-positive neurones (left panels) and PGP 9.5 (right panels) are depicted in (C). (D)
Summarizes the TUNEL data in DRG from control and diabetic rats. TUNEL-positive neurones were detected in 0.10 ± 0.08% of
control neurones and 1.8 ± 0.15% of diabetic neurones (n ¼ 10, P < 0.05). Scale bar equals 50 lm.
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diabetic neurones were caspase-3-positive (n ¼ 10,
P < 0.05). These results are summarized in a histogram
presented in Fig. 2B. Representative adjacent sections
from nodose ganglia from control (top panels) and
diabetic (bottom panels) rats processed for TUNEL-
positive neurones (left panels) and PGP 9.5 (right
panels) are depicted in Fig. 2C. Fig. 2D summarizes
the TUNEL data in nodose ganglia from control and
diabetic rats. TUNEL-positive neurones were detected
in 0.20 ± 0.08% of control DRG neurones and
1.2 ± 0.2% of DRG neurones from diabetic rats





Figure 2 Activated caspase-3 and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling (TUNEL)-positive
neurones were significantly increased in nodose ganglia from diabetic rats compared with controls. (A) Depicts the results in
adjacent sections involving PGP 9.5-positive cells (right panels) that also demonstrated activated caspase-3-positive (left panels) in
nodose ganglia from control (top panels) and diabetic (bottom panels) rats. The results are summarized in a histogram presented in
(B). When assessment of caspase-3-positive neurones was limited to cells that demonstrated grade 4 staining, 0.18 ± 0.05% of
control neurones and 1.4 ± 0.2% of diabetic neurones were caspase-3-positive (n ¼ 10, P < 0.05). Representative adjacent sections
from nodose ganglia from control (top panels) and diabetic (bottom panels) rats processed for TUNEL-positive neurones (left panels)
and PGP 9.5 (right panels) are depicted in (C). (D) Summarizes the TUNEL data in nodose ganglia from control and diabetic rats.
TUNEL-positive neurones were detected in 0.20 ± 0.08% of control DRG neurones and 1.2 ± 0.2% of DRG neurones from diabetic
rats (n ¼ 10, P < 0.05). Scale bar equals 35 lm.
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Activated caspase-3 and TUNEL-positive
neurones were significantly increased in the
colon myenteric plexus from diabetic rats
compared with controls
Fig. 3A depicts the results in adjacent sections showing
PGP 9.5-positive cells (right panels) that also demon-
strated activated caspase-3-positive (left panels) in the
colon myenteric plexus from control (top panels) and
diabetic (bottom panels) rats. The results are summar-
ized in a histogram presented in Fig. 3B for neurones
demonstrating grade 4 staining, 0.2 ± 0.1% of control
neurones and 1.4 ± 0.08% of diabetic neurones were
caspase-3-positive (n ¼ 10, P < 0.05). We found grading
the intensity of activated caspase-3 IR in the cross-
sections of colon myenteric plexus challenging because
many neurones demonstrated a suboptimal surface






Figure 3 Activated caspase-3 and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling (TUNEL)-positive
neurones were significantly increased in the colon myenteric plexus from diabetic rats compared with controls and reversed by
treatment with insulin. (A) Depicts the results in adjacent sections showing PGP 9.5-positive cells (right panels) that also dem-
onstrated activated caspase-3-positive (left panels) in the colon myenteric plexus from control (top panels) and diabetic (bottom
panels) rats. The results are summarized in a histogram presented in (B) for neurones demonstrating grade 4 staining. 0.2 ± 0.1% of
control neurones and 1.4 ± 0.08% of diabetic neurones were caspase-3-positive (n ¼ 10, P < 0.05). Representative adjacent sections
of colon from control (top panels) and diabetic (bottom panels) rats processed for TUNEL-positive neurones (left panels) and PGP 9.5
(right panels) are depicted in (C). (D) Summarizes the TUNEL data involving assessment of colon myenteric neurones from control
and diabetic rats. TUNEL-positive neurones were detected in 0.08 ± 0.05% of control dorsal root ganglion (DRG) neurones and
1.1 ± 0.15% of DRG neurones from diabetic rats (n ¼ 10, P < 0.05). (E) After 1 month of diabetes, 2 weeks of insulin-mediated
euglycaemia reversed the percentage of TUNEL-positive neurones in the myenteric plexus of diabetic rats to control levels
(n ¼ 4, P < 0.05). Scale bar equals 35 lm.
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staining intensity. To a first approximation, the
variable intensity of staining observed in DRG and
vagus nodose ganglion neurones was also apparent in
the colon myenteric neurones. We did observe a level
of grade 4 caspase-3 IR neurones (1–2%) and TUNEL-
positive neurones in the myenteric plexus that was
similar to the nodose ganglion and DRG preparations.
Representative adjacent sections of colon from control
(top panels) and diabetic (bottom panels) rats processed
for TUNEL-positive neurones (left panels) and PGP 9.5
(right panels) are depicted in Fig. 3C. Fig. 3D summar-
izes the TUNEL data involving assessment of colon
myenteric neurones from control and diabetic rats. The
TUNEL-positive neurones were detected in 0.08 ±
0.05% of control DRG neurones and 1.1 ± 0.15% of
DRG neurones from diabetic rats (n ¼ 10, P < 0.05).
We also examined the effect of 2 weeks of insulin-
mediated euglycaemia on the percentage of TUNEL-
positive neurones. Insulin treatment was initiated
1 month after onset of diabetes. As depicted in Fig. 4E,
insulin treatment reversed the percentage of TUNEL-
positive neurones to control levels (n ¼ 4, P < 0.05).
Double-labelling for activated caspase-3 and
TUNEL-positive neurones were increased in
DRGs from diabetic rats compared with controls
To confirm the observations generated using adjacent
sections we performed double-label immunohisto-
chemistry to detect TUNEL-positive and activated
caspase-3-positive neurones in the same section in
DRGs from control and diabetic rats. We used DRGs
for these confirmatory studies because of the relative
ease to identify neuronal soma and quantify the
intensity of caspase-3 immunoreactvity to compare
with the results using adjacent sections. Sections of
mouse breast cancer were processed in parallel and
served as a positive control for the double-label assay.
Sections not exposed to the primary antibody served as
a negative control for the assay. Fig. 4A depicts the
positive controls for activated caspase-3 (left panel) and
TUNEL, after exposure to TdT enzyme to nick DNA




Figure 4 Double-labelling for activated caspase-3 and ter-
minal deoxynucleotidyl transferase-mediated dUTP nick-end
labelling (TUNEL)-positive neurones were increased in dorsal
root ganglion (DRG) from diabetic rats compared with con-
trols. To confirm the observations generated using adjacent
sections, we performed double-label immunohistochemistry
to detect TUNEL-positive and activated caspase-3-positive
neurones in the same section in DRGs from control and dia-
betic rats. Sections of mouse breast cancer were processed in
parallel and served as a positive control for the double-label
assay. Sections not exposed to the primary antibody served as
a negative control for the assay. (A) Depicts the positive
controls for activated caspase-3 (left panel) and TUNEL, after
exposure to TdT enzyme to nick DNA (right panel) using
mouse breast cancer tissue. (B) Demonstrates a representative
DRG neurone that was activated caspase-3-positive and
TUNEL-negative (left panel). Right panel demonstrates a DRG
neurone that was both caspase-3-positive and TUNEL-posit-
ive. The results of the double-label studies are summarized in
histograms presented in (C) for activated caspase-3 immuno-
reactive neurones. When neurones demonstrating grades 1–4
staining were included in the assessment, caspase-3-positive
neurones represented 0.4 ± 0.18% of the total neuronal pop-
ulation in controls and 6 ± 1.5% of the neurones in DRG from
diabetic rats. When assessment of caspase-3-positive neurones
was limited to cells that demonstrated only grade 4 staining,
0.15 ± 0.08% of control neurones and 1.6 ± 0.2% of diabetic
neurones were caspase-3-positive (n ¼ 10, P < 0.05). (D)
Summarizes the double-label data for neurones that were both
caspase-3-positive and TUNEL-positive. TUNEL-positive
cells typically demonstrated grade 4 and occasionally grade
3-activated caspase-3 immunoreactivity. Neurones that were
positive for both caspase-3 and TUNEL were detected in
0.10 ± 08% of control DRG neurones and 1.1 ± 0.15% of DRG
neurones from diabetic rats (n ¼ 10, P < 0.05). Scale bar equals
50 lm.
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(left panel) demonstrates a representative DRG neur-
one that was activated caspase-3-positive and TUNEL-
negative. Fig. 4B (right panel) demonstrates a DRG
neurone that was both caspase-3-positive and TUNEL-
positive. These results confirm that it is possible to
observe activation of caspase-3 without evidence of
being TUNEL-positive. The results of the double-label
studies are summarized in histograms presented in
Fig. C for activated caspase-3-immunoreactive neu-
rones. When neurones demonstrating grades 1–4 stain-
ing were included in the assessment, caspase-3-
positive neurones represented 0.4 ± 0.18% of the total
neuronal population in controls and 6 ± 1.5% of the
neurones in DRG from diabetic rats. When assessment
of caspase-3-positive neurones was limited to cells that
demonstrated only grade 4 staining, 0.15 ± 0.08% of
control neurones and 1.6 ± 0.2% of diabetic neurones
were caspase-3-positive (n ¼ 10, P < 0.05). Fig. 4D
summarizes the double-label data for neurones that
were both caspase-3-positive and TUNEL-positive. The
TUNEL-positive cells typically demonstrated grade 4
and occasionally grade 3-activated caspase-3 IR. Neu-
rones that were positive for both caspase-3 and TUNEL
were detected in 0.10 ± 08% of control DRG neurones
and 1.1 ± 0.15% of DRG neurones from diabetic rats
(n ¼ 10, P < 0.05). Therefore, we observed a significant
percentage of neurones that were activated caspase-
3-positive but TUNEL-negative in the preparations
from diabetic rats. These results were similar to those
involving adjacent sections.
DISCUSSION
We believe that this is the first report to assess the
level of apoptosis that occurs in situ in three peripheral
nerve populations in early diabetic neuropathy. Our
results extend previous studies in a significant manner
by implicating apoptosis as a contributing factor to the
complications of diabetes affecting the autonomic
nervous system, specifically vagal afferent and myen-
teric plexus neurones, in addition to DRG neurones.
After 1 month of diabetes, 2 weeks of insulin-induced
euglycaemia reversed the level of apoptosis observed in
the myenteric plexus to control levels. This comple-
ments our previous observation in primary afferent
(DRG) neurones that insulin treatment can reverse
functional abnormalities in early diabetes.
Apoptosis is a regulated cell suicide programme that
plays an important role in many biological processes
including embryonic development, response to
tumours to chemotherapy and the pathogenesis of neu-
rodegenerative diseases.28 The detection of fragmented
DNA strand ends, such as with the TUNEL assay, has
been used to characterize apoptotic tissues, but are
subject to misinterpretation because necrotic cells also
generate fragmented DNA strands.29 It has also been
reported that in some cells DNA fragmentation is
reparable and not indicative of certain cell death.30
Based on studies of the molecular events in apopto-
sis, it is generally accepted that cleavage of substrates
by caspases is an essential and characteristic feature of
activation of the apoptosis cascade.31 Caspases that
participate in the apoptosis cascade have been divided
into initiators and executioners. The exact order of the
executioners and the position of specific caspases in
the apoptotic pathway are still under investigation, but
caspases-3, -6, and -7 are generally accepted to be
executioners. Caspase-3 is considered a key effector
caspase in many cells and mediates the cleavage of
itself, other downstream caspases and other caspase
substrates. Activation of caspase-3 precedes the frag-
mentation of DNA detected by TUNEL. It is unclear
whether, once activated, the apopotosis cascade is
reversible and, if reversible, at what point in the
cascade reversibility is lost. We stratified the intensity
of activated caspase-3 IR using a 1–4 scale with 1 being
the weakest and 4 the most intense staining. Employ-
ing this scale, the percentage of neurones with grade 4
caspase-3 IR was similar to the level of apoptosis that
we detected using the TUNEL method, i.e. c. 1–2%.
When we included all levels (grades 1–4) of caspase-3
immunoreactive neurones, the level of caspase-3 acti-
vation increased to 6–8%. Our data support that it is
possible upstream members of the apoptosis cascade
(caspases) can be activated to a greater degree than the
terminal events measured by TUNEL. If true, this
suggests that it is possible activation of caspase-3 does
not commit a cell to obligatory death. For example, in
Caenorhabditis elegans, CED 3-positive cells (the
homologue of mammalian caspase-3) survive and
differentiate.32 It is possible that caspase-independent
nuclear fragmentation may occur. For example, hyper-
glycaemia-mediated nuclear fragmentation was not
linked to caspases.33 Another recent study found that
activation of caspase-3 in long-term STZ-induced
diabetes may not be inexorably linked to apoptosis.34
Markers of apoptosis were not increased in DRGs
obtained from diabetic rats despite evidence for acti-
vation of casapase-3. It is unclear why these results
differ from other reports supporting activation of
apoptosis in DRGs from diabetic rats although differ-
ences in the methods and experimental design may
explain these discrepancies. It is relevant that the
percentage of activated caspase-3 immunoreactive
neurones that we observed with grade 4 staining
(1–2%) was similar to that reported in DRGs by
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Schmeichel et al.14 Of interest, the level of apoptosis
that this group observed after 1 month and 12 months of
diabetes was not significantly different. We reported
previously a level of apoptosis of 6–8% in acutely
dissociated DRG neurones from early diabetic rats
compared with 2–4% in control neurones.5. Similar
levels of apoptosis were observed by Schmiechel et al.14
It is possible that the different levels of apoptosis
observed in the current study and our previous report
are related to the different methods employed to fix the
tissue, i.e. in situ fixation in the current study vs fixation
after removal of the tissue in our previous study.
Diabetic neuropathy may be associated with a
differential effect on neuronal loss that correlates with
the soma size in lumbar DRG neurones.16 Specifically,
morphometric analysis suggested that diabetic neur-
opathy was associated with preferential drop out (by
43%) of the largest diameter (>50 lm) DRG neurones
after 1 year of diabetes. There was no significant
difference in total DRG neurone counts. Therefore,
the mechanisms influencing neuronal drop out in
diabetic neuropathy may preferentially affect periph-
eral sensory neurones with larger soma.
Diabetic autonomic neuropathy is accompanied by
alterations in autonomic and visceral afferent neu-
rones.1,24 Demyelination of axons in the vagus nerve
occurs with diabetic neuropathy. In addition, degener-
ation and regeneration of unmyelinated vagal nerve
fibres have also been reported in patients with diabetic
gastropathy. Diabetes affects the content of some but
not all neuroactive agents in the nodose ganglion.26,35
Neurotrophins have been shown to play an important
role in the survival and maintenance of peripheral
somatic and autonomic neurones.9,26,36 Therefore,
reduced availability and/or function of neurotrophins
may contribute to the development and progression of
diabetic neuropathy.
A loss of myenteric neurones has been reported in
short-term STZ-induced diabetes.19,20 This effect
appears to be more pronounced in the colon compared
with the proximal gut.19,24 The mechanism(s) under-
lying the loss of neurones were not explored in these
reports. These observations along with clinical evi-
dence that colonic motor dysfunction is a relatively
early complication in diabetes led us to focus on
whether apoptosis is present in the colon myenteric
plexus in early diabetic neuropathy.
Assessment of the pathophysiological significance
of apoptosis occurring at a level of 1–2% in diabetic
neuropathy is a challenging issue. A low level of
apoptosis is consistent with the slow, progressive
natural history for DAN that typically takes years to
become clinically evident. We examined the presence
of apoptosis between 4 and 8 weeks after the onset of
diabetes, e.g. relatively early in the course of the
disease. Additional studies will be required to deter-
mine whether the level of apoptosis remains constant
over time, increases or decreases. It will also be
important to assess whether activation of the apop-
tosis cascade differentially affects subpopulations of
neurones in a region-specific manner.
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